Physician profile
Frank J Pinto
NPI 1043212350
$18,157.49
in general payments reported to CMS, 2019-2025
40 companies · $3,955 in 2025
The $3,955 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,481 · 2020: $449 · 2021: $1,489 · 2022: $3,265 · 2023: $3,260 · 2024: $3,258 · 2025: $3,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,154.47 |
| Education | $319.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,497.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,990.16 | 2019-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $1,633.78 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $1,483.24 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,257.07 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Genzyme Corporation | $1,160.72 | 2019-2025 | |
| Lilly USA, LLC | $1,103.40 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $932.32 | 2019-2025 | |
| Leo Pharma INC. | $656.37 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Amgen INC. | $646.25 | 2019-2025 | Otezla, Enbrel, Otezla |
| Incyte Corporation | $529.38 | 2021-2025 | Opzelura |
| Ucb, INC. | $425.77 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $362.75 | 2019-2025 | Cabtreo, Jublia |
| Galderma Laboratories, L.P. | $250.84 | 2020-2025 | Aklief, Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $206.01 | 2019-2023 | Valchlor |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $198.90 | 2019-2024 | Xolair, Erivedge |
| E.R. Squibb & Sons, L.L.C. | $192.76 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.28 | 2023-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $160.73 | 2023-2025 | Zoryve |
| Organon LLC | $141.48 | 2025 | Vtama |
| Biofrontera INC. | $133.91 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $121.65 | 2022-2024 | Vtama |
| Dusa Pharmaceuticals, INC. | $101.61 | 2019 | |
| Mayne Pharma Commercial LLC | $100.23 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $98.86 | 2019 | |
| Blueprint Medicines Corporation | $81.83 | 2023-2024 | Ayvakit |
| Botanix Sb INC | $66.87 | 2025 | Sofdra |
| Medtronic Vascular, INC. | $59.29 | 2020 | |
| Allergan, INC. | $54.71 | 2019-2021 | |
| Royal Biologics, INC. | $48.97 | 2024 | |
| Mission Pharmacal Company | $43.04 | 2019 | |
| Epi Health, LLC | $39.70 | 2022 | |
| Dermira, INC. | $36.50 | 2019 | |
| Strata Skin Sciences, INC. | $31.83 | 2022-2023 | Xtrac |
| Janssen Scientific Affairs, LLC | $29.28 | 2019 | |
| Medtronic, INC. | $24.96 | 2021 | |
| Lnhc, INC | $24.81 | 2025 | Zelsuvmi |
| Almirall LLC | $23.04 | 2022 | |
| Prugen, INC. Pharmaceuticals | $21.55 | 2019 | |
| Celgene Corporation | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.